2025-12-30 - Analysis Report
Okay, here's a comprehensive report on Natera Inc. (NTRA) based on the data you provided, broken down into simple numbers, analysis, and a final summary.

**1) Return Rate Comparison:**

*   **NTRA Company Overview:** Natera Inc. is a genetic testing company focusing on non-invasive prenatal testing (NIPT) and cancer diagnostics.
*   **NTRA Cumulative Return:** 139.49%
*   **VOO (S&P 500) Cumulative Return:** 103.47%
*   **Divergence:** 36.5 (Relative Divergence: 47.5)

**Analysis:**

*   NTRA has outperformed the S&P 500 significantly over the period measured, as evidenced by the higher cumulative return.
*   The divergence of 36.5 indicates NTRA's return is currently 36.5 percentage points higher than the S&P 500's return.
*   The relative divergence of 47.5 suggests the current divergence is near the middle of its historical range.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD   | Alpha  | Beta  | Cap(B) |
|------------|---------|-------|--------|-------|--------|
| 2015-2017  | -10.0%  | 70.1% | -34.0% | -0.2  | 1.2    |
| 2016-2018  | 22.0%   | 80.0% | 6.0%   | 0.1   | 1.9    |
| 2017-2019  | 50.0%   | 80.0% | 28.0%  | 1.0   | 4.7    |
| 2018-2020  | 186.0%  | 80.5% | 163.0% | 1.1   | 13.7   |
| 2019-2021  | 96.0%   | 80.5% | 49.0%  | 1.6   | 12.9   |
| 2020-2022  | -77.0%  | 80.5% | -76.0% | 0.1   | 5.5    |
| 2021-2023  | -194.0% | 76.6% | -195.0%| -1.1  | 8.6    |
| 2022-2024  | 8.0%    | 76.6% | -13.0% | -1.2  | 21.8   |
| 2023-2025  | 167.0%  | 76.6% | 99.0%  | 0.1   | 32.2   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows volatile performance over different periods, with periods of high growth (e.g., 2018-2020) and significant declines (e.g., 2021-2023).
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating significant risk and volatility in the stock's price.
*   **Alpha:** Alpha measures the stock's performance relative to a benchmark (presumably the S&P 500). The values fluctuate significantly, showing periods of outperformance (positive alpha) and underperformance (negative alpha). The alpha is significantly negative in the periods 2015-2017, 2020-2022, 2021-2023, 2022-2024.
*   **Beta:** Beta measures the stock's volatility relative to the market. Beta values vary, indicating different levels of correlation with the market. Some periods show a higher beta (e.g., 2019-2021), suggesting the stock is more sensitive to market movements. Beta is negative for the periods 2015-2017, 2021-2023, 2022-2024.
*   **Cap(B):** Market capitalization trend, which indicates strong growth in 2018-2020, then it is reduced and recovered from 2022.

**2) Recent Stock Price Fluctuations:**

*   **Current Price:** 231.3
*   **Previous Close:** 233.74
*   **Change:** -1.04
*   **5-day SMA:** 234.44
*   **20-day SMA:** 234.37
*   **60-day SMA:** 208.40

**Analysis:**

*   The stock price has decreased slightly in the most recent trading session.
*   The 5-day and 20-day SMAs are very close, suggesting the stock price has been relatively stable in the short term.
*   The 60-day SMA is significantly lower than the 5-day and 20-day SMAs, indicating an upward trend over the past couple of months.

**3) Indicators Analysis:**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 34.36
*   **PPO:** -0.61
*   **Hybrid Signal:** Buy 100% (Very Safe, MRI: 0.90)
*   **Recent Relative Divergence Change:** -0.1 (Short-term decline)
*   **Expected Return:** -49.9%

**Analysis:**

*   The MRI suggests a high level of confidence in the investment.
*   The RSI of 34.36 indicates that the stock is approaching oversold territory, potentially signaling a buying opportunity.
*   The PPO is negative, which indicates a potential short term bearish trend.
*   The hybrid signal recommends buying.
*   The recent relative divergence change (-0.1) indicates a short-term downward trend.
*   The negative expected return suggests potential challenges in the long term and poor expected future performance compared to the S&P 500.

**4) Recent News & Significant Events:**

*   **Mixed Headlines:** The news headlines present a mixed picture, with some articles suggesting potential growth and positive developments, while others express caution or a "hold" recommendation.
*   **Analyst Interest:** SWS Partners bought shares of Natera, indicating institutional interest.
*   **Conference Presentation:** Natera's presentation at a health conference suggests efforts to increase visibility and potentially attract investment.
*   **MRD Growth:**  An article on Seeking Alpha highlights the importance of Minimal Residual Disease (MRD) growth, which is a key area for Natera.
*   **Positive Coverage:** TradingView highlights positive aspects of the company.

**4-2) Analyst Opinions:**

*   **Consensus:** Strong Buy (1.47)
*   **Target Price:** 246.26 (Average), 285.00 (High), 186.00 (Low)
*   **Recent Rating Changes:** No specific changes listed.

**Analysis:**

*   Analysts are generally positive on Natera, with a consensus rating of "Strong Buy."
*   The average target price of $246.26 suggests potential upside from the current price.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-11-07 | -0.64 | 0.59 B$    |
| 2025-08-08 | -0.74 | 0.55 B$    |
| 2025-05-09 | -0.50 | 0.50 B$    |
| 2024-11-12 | -0.26 | 0.44 B$    |
| 2025-11-07 | -0.26 | 0.44 B$    |

**Analysis:**

*   **EPS:** Natera has consistently reported negative Earnings Per Share (EPS), indicating ongoing losses. While losses appear to be shrinking, it is still negative.
*   **Revenue:** Revenue has been increasing steadily.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|----------------|
| 2025-09-30   | $0.59B     | 64.91%          |
| 2025-06-30   | $0.55B     | 63.41%          |
| 2025-03-31   | $0.50B     | 63.12%          |
| 2024-12-31   | $0.48B     | 62.94%          |
| 2024-09-30   | $0.44B     | 61.79%          |

**Analysis:**

*   **Revenue:** Revenue is showing consistent growth.
*   **Profit Margin:** Profit margin is increasing.

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-09-30   | $1.25B     | -6.99%    |
| 2025-06-30   | $1.25B     | -8.10%    |
| 2025-03-31   | $1.24B     | -5.40%    |
| 2024-12-31   | $1.20B     | -4.50%    |
| 2024-09-30   | $0.88B     | -3.60%    |

**Analysis:**

*   **Equity:** Equity has been relatively stable.
*   **ROE:** Return on Equity (ROE) is negative, reflecting the company's ongoing losses. Although it's negative, it is trending towards zero.

**7) Comprehensive Analysis (Summary):**

*   **Positive Performance vs. S&P 500:** NTRA has significantly outperformed the S&P 500 in cumulative return.
*   **High Volatility:** The stock exhibits high volatility, as evidenced by the high MDD.
*   **Mixed Indicators:** The MRI suggests a buy recommendation, and the RSI hints at oversold conditions, but the negative expected return is concerning.
*   **Analyst Optimism:** Analysts have a "Strong Buy" consensus and expect price appreciation.
*   **Revenue Growth, Persistent Losses:** Natera shows strong revenue growth and improving profit margins, but it still reports losses and has negative ROE.
*   **News is Mixed:** News headlines present a mixed view of the company.

**Overall:**

Natera presents a mixed picture. While it has demonstrated significant outperformance compared to the S&P 500, exhibits high growth, and receives positive analyst ratings, it also carries significant risk due to its high volatility, ongoing losses, and negative expected return. Investors should carefully weigh these factors and consider their risk tolerance before investing in NTRA.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.